Search

Your search keyword '"Worm, M."' showing total 93 results

Search Constraints

Start Over You searched for: Author "Worm, M." Remove constraint Author: "Worm, M." Topic dermatitis, atopic Remove constraint Topic: dermatitis, atopic
93 results on '"Worm, M."'

Search Results

1. Proteomic, miRNA and bacterial biomarker patterns in atopic dermatitis patients and their course upon anti-IL-4Rα therapy.

2. Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials.

3. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.

4. S3 guideline Atopic dermatitis: Part 2 - Systemic treatment.

5. S3 Guideline Atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groups.

6. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.

7. Itch, sleep loss, depressive symptoms, fatigue, and productivity loss in patients with moderate-to-severe atopic dermatitis: Analyses of TREATgermany registry data.

9. [New guideline and treatment options for hand eczema].

10. Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.

11. Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany.

14. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.

15. Mast cells instruct keratinocytes to produce thymic stromal lymphopoietin: Relevance of the tryptase/protease-activated receptor 2 axis.

16. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7).

18. Perception of the coronavirus pandemic by patients with atopic dermatitis - Results from the TREATgermany registry.

20. Tralokinumab in atopic dermatitis.

21. Safety of dupilumab in patients with atopic dermatitis: expert opinion.

22. Targeted Use of Placebo Effects Decreases Experimental Itch in Atopic Dermatitis Patients: A Randomized Controlled Trial.

23. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.

24. Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study.

25. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

26. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.

27. Atopic skin diathesis rather than atopic dermatitis is associated with specific contact allergies.

28. Update "Systemic treatment of atopic dermatitis" of the S2k-guideline on atopic dermatitis.

29. Modern therapies in atopic dermatitis: biologics and small molecule drugs.

30. Implementation of dupilumab in routine care of atopic eczema: results from the German national registry TREATgermany.

31. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.

32. Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients.

33. The role of mobile health technologies in allergy care: An EAACI position paper.

34. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.

35. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials.

36. Transcriptomic and lipidomic profiling of eicosanoid/docosanoid signalling in affected and non-affected skin of human atopic dermatitis patients.

37. [Decreased professional performance and quality of life in patients with moderate-to-severe atopic eczema : Results from the German atopic eczema registry TREATgermany].

38. Propionibacterium acnes Abundance Correlates Inversely with Staphylococcus aureus: Data from Atopic Dermatitis Skin Microbiome.

39. Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial.

40. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.

41. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

42. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).

43. A Promoter Polymorphism of the Vitamin D Metabolism Gene Cyp24a1 is Associated with Severe Atopic Dermatitis in Adults.

44. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

45. [Not Available].

46. S2k guideline on diagnosis and treatment of atopic dermatitis--short version.

47. Malassezia spp.-specific immunoglobulin E level is a marker for severity of atopic dermatitis in adults.

48. Clinical efficacy and tolerability of a novel selective corticosteroid in atopic dermatitis--two randomised controlled trials.

49. Impact of comorbidities on the treatment of atopic dermatitis in clinical practice.

50. Commentary on ''dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3β activation''.

Catalog

Books, media, physical & digital resources